氟氯西林为耐金葡球菌酶的半合成青霉素 ,临床上主要用于治疗产酶的金葡球菌引起的皮肤软组织感染、呼吸道感染、外科及耳鼻喉科感染。本试验采用由香港澳美公司生产的氟氯西林胶囊 ,治疗轻中度细菌性感染 12 0 1例 ,剂量 2 5 0～ 5 0 0 mg,每日 3次 ,疗程 5 d,旨在对其进行不作皮试的临床安全性和有效性评价。结果表明 ,由敏感革兰氏阳性菌引起的轻中度感染 ,用氟氯西林治疗具有较好的临床疗效 ,其临床有效率为 90 .1%。 12 0 1例病例中 ,进行细菌学评价 2 91例 ,分离出致病菌 2 0 3株 ,治疗结束时 179株菌被清除 ,细菌清除率为 88.2 %。 12 0 1例受试者中 ,出现临床不良反应的病例 36例 ,其发生率是 2 .99% ,出现肝功异常者 1例。其中与药物有关的临床急、慢性不良反应发生率分别为 0 .6 7%和 1.33%。主要临床不良反应表现为胃肠不适、恶心、皮肤痒等 ,无一例发生过敏性休克 Flucloxacillin is a semisynthetic penicillin-resistant Staphylococcus aureus, clinically used mainly for the treatment of Staphylococcus aureus-induced skin and soft tissue infections, respiratory infections, surgical and otolaryngological infections. In this study, 1,25 cases of mild to moderate bacterial infections were treated with flucloxacil capsules from Hong Kong, Macao and the United States at a dose of 250 to 500 mg three times a day for 5 days to treat them Evaluation of clinical safety and effectiveness without dermal test. The results showed that mild to moderate infections caused by sensitive Gram-positive bacteria, flucloxacillin treatment has a good clinical efficacy, the clinical effective rate was 90.1%. Of 121 cases, 291 cases were bacteriologically evaluated and 203 pathogens were isolated. At the end of treatment, 179 strains were removed and the bacterial clearance rate was 88.2%. Thirty-six cases of clinical adverse reactions were found in 12 0 1 subjects, with a rate of 2.99% and 1 case of abnormal liver function. Including clinical drug-related acute and chronic adverse reactions were 0.67% and 1.33%. The main adverse clinical manifestations of gastrointestinal discomfort, nausea, itchy skin, no case of anaphylactic shock